Top Markets
#1 Siren Siren +30.45%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +26.06%
#3 OriginTrail OriginTrail +21.43%
#4 DogBull DogBull +14.01%
#5 MarsCoin MarsCoin +12.76%
#6 COTI COTI +9.75%
#7 Xphere Xphere +6.05%
#8 Concordium Concordium +6.00%
#9 PulseChain PulseChain +5.89%
#10 Pons Pons +5.77%
Coin of the day
Siren Siren
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
RaQualia Pharma Inc. RaQualia Pharma Inc.

RaQualia Pharma Inc.

4579
Classement en actions #22339
RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a... RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegoprazan, designed to treat gastroesophageal reflux disease (GERD), is currently undergoing Phase 1 clinical trials in the United States. Grapiprant is in Phase II development in the U.S. and Phase I in China for pain management; it is also being investigated in Phase I studies in both the U.S. and China for its potential in cancer therapy. Beyond human medicines, RaQualia Pharma develops a range of veterinary products. These include grapiprant for managing osteoarthritis in dogs, a ghrelin receptor agonist aimed at addressing cancer-related anorexia/cachexia syndrome and constipation stemming from spinal cord injury, and ELURA, a medication for combating weight loss in cats suffering from chronic kidney disease. The company's extensive R&D pipeline also covers various other therapeutic areas. This includes a TRPM8 blocker for neuropathic pain, a motilin receptor agonist targeting gastrointestinal motility disorders such as gastroparesis, functional dyspepsia, and post-operative ileus, and a potassium-competitive acid blocker for GERD, which has successfully concluded Phase 1 clinical trials. Further early-stage developments encompass a 5-HT4 partial agonist for gastroparesis, functional dyspepsia, and chronic constipation; a 5-HT2B antagonist for irritable bowel syndrome with diarrhea; EP4 antagonists for canine pain management and, in separate Phase I trials, for cancer and general pain indications; a serotonin 5-HT2A and dopamine D2 receptor blocker for schizophrenia; a Cyclooxygenase-2 inhibitor (Phase I for pain); a CB2 agonist; a selective sodium channel blocker; a P2X7 receptor antagonist (Phase I for neuropathic pain); and a retinoic acid receptor alpha agonist. To further its research and development initiatives, RaQualia maintains strategic partnerships with Interprotein Corporation, ASKA Pharmaceutical Co., Ltd., and Epigeneron, Inc.
Prix de l'action
$3.69
Dernière synchronisation: 2026-08-21
Capitalisation boursière
$90.16M
Changement (1 jour)
-3.58%
Changement (1 an)
0.33%
Pays
JP
Échange RaQualia Pharma Inc. (4579)

Catégorie

Healthcare
Nombre d'actions en circulation pour RaQualia Pharma Inc. (4579)
Nombre d'actions en circulation au August 2026: 0
Selon les derniers rapports financiers et le cours de l'action de RaQualia Pharma Inc., le nombre actuel d'actions en circulation est de 0. À la fin de August 2026, l'entreprise avait 0 actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de RaQualia Pharma Inc. (4579) de 2026 à 2026
Actions en circulation à la fin de chaque année
Année Actions en circulation Changez
Pas assez de données pour les dates fournies.
Actions en circulation pour des entreprises similaires ou concurrentes
Entreprise Actions en circulation Différence Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH